Tardive Dyskinesia - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for tardive dyskinesia including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentation such as therapy, route of administration, and target.

Overview of the drug development pipeline for tardive dyskinesia

It has been observed that a major cause of tardive dyskinesia is certain antipsychotic medications that are generally prescribed for conditions such as schizophrenia and schizoaffective disorders. The common symptoms of tardive dyskinesia are characterized by repetitive, involuntary, and jerking movements in the face, neck, and tongue. Symptoms of tardive dyskinesia also include lip smacking, puckering, and pursuing, grimacing, rapid eye blinking, and repetitive chewing. Tardive dyskinesia is a socially stigmatizing long-term disorder where the muscle movements of the patient get out of control, especially in the face, neck, and tongue. The symptoms of tardive dyskinesia can be very troubling for the patients and family members. The use of neuroleptic drugs is also a primary cause of tardive dyskinesia. Several public and private companies are focused on the development of drug molecules for the treatment of tardive dyskinesia. Monotherapy is emerging as the most efficient approach for the treatment of tardive dyskinesia.

According to this pipeline analysis report, all the drug molecules in the pipeline are being developed for the treatment of tardive dyskinesia. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Want a bigger picture? Try a FREE sample of this report now!

Pipeline analysis report on drug development for tardive dyskinesia: Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of tardive dyskinesia. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are

• Adamas Pharmaceuticals
• Contera Pharma
• Medicure
• Mitsubishi Tanabe Pharma
• SOM Biotech

Therapeutic assessment of the drug development pipeline for tardive dyskinesia by route of administration

• Oral
• Unknown

The oral route of administration (ROA) involves the administration of the drug directly into the mouth cavity, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for tardive dyskinesia by therapy

• Monotherapy

According to this pipeline analysis report, all the molecules that are currently in the drug pipeline tardive dyskinesia are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug therapy molecules in the various development stages for tardive dyskinesia?
• What are the companies that are currently involved in the development of drug molecules for tardive dyskinesia?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.